^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ANXA1 (Annexin A1)

    i
    Other names: ANXA1, ANX1, LPC1, Annexin A1
    1d
    Sex-specific hypothalamic PVN transcriptomic signatures of blood pressure autonomic regulation and neuroinflammation in hypertension. (PubMed, Biol Sex Differ)
    These results provide new insights into the cardiovascular and molecular basis of sex differences in hypertension, suggesting distinct neurohumoral autonomic profile in males, whereas in females a greater anti-inflammatory component. These findings offer a valuable framework for developing future sex-specific therapeutic strategies.
    Journal
    |
    ANXA1 (Annexin A1) • AIM2 (Absent In Melanoma 2) • BDNF (Brain Derived Neurotrophic Factor) • S100B (S100 Calcium Binding Protein B)
    11d
    Mesenchymal Stem Cell-Derived Exosomes Reprogram Chemosensitivity Pathways in Cervical Cancer Spheroids. (PubMed, Int J Mol Sci)
    In contrast, SiHa spheroids represented selective responses: MSC-exosome pretreatment did not enhance sensitivity to paclitaxel-cisplatin but improved responsiveness to paclitaxel-carboplatin, particularly within the spheroid core. Overall, MSC-exosome pretreatment exerts cell type and drug-specific effects in CC spheroids, supporting their potential to modulate chemotherapy response.
    Journal
    |
    LGALS1 (Galectin 1) • ANXA1 (Annexin A1) • PKM (Pyruvate Kinase M1/2)
    |
    cisplatin • carboplatin • paclitaxel
    27d
    Repurposing Rosiglitazone Induces Apoptosis Accompanied by Impaired Antioxidant Defense in Cholangiocarcinoma Cells: Findings from Proteomic and Functional Analyses. (PubMed, Pharmaceuticals (Basel))
    Its apoptosis-inducing effect is independent of PPARγ activation. These findings underscore the therapeutic potential of RSG for CCA treatment.
    Journal
    |
    CASP3 (Caspase 3) • ANXA1 (Annexin A1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CASP7 (Caspase 7)
    |
    rosiglitazone
    29d
    Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance. (PubMed, J Extracell Vesicles)
    In summary, we demonstrate that protein profiling of EVs in relation to osimertinib refractoriness has the potential to identify possible biomarkers that can indicate osimertinib treatment resistance, for example, CSPG4, HSPG2, TAGLN, TNC, THBS1, ANXA1 and CD73/NT5E. Studies in expanded cohorts should be conducted to further validate these putative osimertinib biomarkers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • FOLR1 ( Folate receptor alpha ) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto) • CSPG4 (Chondroitin Sulfate Proteoglycan 4) • LAMP3 (Lysosomal Associated Membrane Protein 3) • ANXA1 (Annexin A1) • L1CAM (L1 cell adhesion molecule) • TAGLN (Transgelin)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    1m
    Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression. (PubMed, Cancer Cell)
    We nominate ANXA1 and HMOX1 as surrogate cell surface markers for a subpopulation we term malignancy associated GAMs (mGAMs) which possess distinct pro-tumorigenic properties, share partial ontogeny with peripheral blood monocytes, and are enriched in newly transformed regions of glioma. mGAMs potentially play a pivotal role in glioma progression and represent a plausible therapeutic target.
    Journal
    |
    HMOX1 (Heme Oxygenase 1) • ANXA1 (Annexin A1) • FOSL2 (FOS Like 2)
    1m
    Clinical characteristics and spatial transcriptome analysis of non-small cell lung cancers exhibiting early alectinib resistance: a retrospective OLCSG study. (PubMed, Cancer Res Commun)
    ANXA1 may play an important role in mediating early resistance. New treatment options for the early resistance group are required.
    Retrospective data • Journal
    |
    ALK (Anaplastic lymphoma kinase) • IL6 (Interleukin 6) • ANXA1 (Annexin A1)
    |
    ALK positive • ALK rearrangement
    |
    Alecensa (alectinib)
    1m
    ANXA1 overexpression promotes B cell acute lymphoblastic leukemia progression and resistance by regulating fatty acid metabolism through PI3K/Akt signaling. (PubMed, Mol Cell Biochem)
    Then in vivo results indicated that downregulation of ANXA1 in B-ALL cells could significantly reduce leukemic cell burden and increase dexamethasone sensitivity. Therefore, ANXA1 was identified as an oncogene in the development and progression of B-ALL and might be a promising biomarker for treating B-ALL.
    Journal
    |
    ANXA1 (Annexin A1) • FASN (Fatty acid synthase) • ACACA (Acetyl-CoA Carboxylase Alpha)
    |
    dexamethasone
    2ms
    PRSS22 promotes the immune evasion of gastric cancer via inhibiting ANXA1-mediated degradation of PD-1. (PubMed, Food Nutr Res)
    PRSS22 suppressed ANXA1-mediated degradation of PD-1 in T cell to promote the immune evasion of GC. Targeting PRSS22 is thus a potentially effective therapeutic strategy for GC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • ANXA1 (Annexin A1) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • CASP9 (Caspase 9) • FOXP3 (Forkhead Box P3) • CASP7 (Caspase 7) • SLC2A1 (Solute Carrier Family 2 Member 1)
    2ms
    Physiological and pathological roles of ANXA11: a multifunctional regulator in neurodegeneration and other disorders. (PubMed, Cell Commun Signal)
    In this review, we comprehensively explored the physiological and pathological roles of ANXA11 in neurodegeneration and other disorders, with a focus on LLPS, membrane dynamics, and amyloidogenesis. We discussed potential therapeutic strategies targeting the unique properties of ANXA11 and proposed several critical scientific questions that need to be explored.
    Review • Journal
    |
    TARDBP (TAR DNA Binding Protein) • ANXA1 (Annexin A1) • ANXA11 (Annexin A11)
    2ms
    Immune Microenvironment Signatures Predict Response and Survival in Rectal Cancer Patients After Neoadjuvant Chemoradiation. (PubMed, Anticancer Res)
    Immune-related gene expression patterns are associated with response to nCRT in rectal cancer. High expression levels of S100A8, SPINK5, ANXA1, FOXJ1, and CLEC7A were indicative of favorable treatment response, and S100A8 and SPINK5 were associated with prognosis. A machine learning-based model composed of immune-related genes showed strong predictive potential. Our results support the use of immune gene signatures to guide personalized therapy in rectal cancer.
    Journal
    |
    MUC1 (Mucin 1) • S100A8 (S100 Calcium Binding Protein A8) • ANXA1 (Annexin A1) • CCND3 (Cyclin D3) • TLR4 (Toll Like Receptor 4) • CLEC7A (C-Type Lectin Domain Containing 7A) • TNFRSF10B (TNF Receptor Superfamily Member 10b) • CREB5 (CAMP Responsive Element Binding Protein 5) • DUSP4 (Dual Specificity Phosphatase 4) • TCF7 (Transcription Factor 7)
    2ms
    Integrative machine learning reveals hidden and emerging co-regulatory gene networks for multi-phase glioblastoma outcome prediction. (PubMed, Eur J Cancer)
    Overall, our findings through the computational approach underscore the significance of co-regulatory gene networks in GBM biology. It also demonstrates how integrating transcriptomic and protein-level interactions can refine prognostic modeling, advance biomarker discovery, and inform future therapeutic development.
    Journal
    |
    ANXA1 (Annexin A1) • CSF1R (Colony stimulating factor 1 receptor) • ITGAM (Integrin, alpha M)
    2ms
    Integrative molecular-radiopathomic characterization of AIRE-driven immune subtypes in bladder cancer. (PubMed, NPJ Digit Med)
    Collectively, this study introduces an AIRE-based immune molecular subtype of BCa and systematically characterizes it across multiple dimensions. By achieving a closed-loop from identification to validation and clinical translation, our findings offer a new perspective for patients most likely to benefit from immunotherapy and advancing precision treatment strategies in bladder cancer.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • ANXA1 (Annexin A1)